Telehealth-Massed Imaginal Exposure for PTSD

Sponsor
Medical University of South Carolina (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05450224
Collaborator
Ralph H. Johnson VA Medical Center (U.S. Fed)
25
1
12

Study Details

Study Description

Brief Summary

The purpose of this study is to establish the safety, feasibility, and acceptability of very brief imaginal exposure therapy for post-traumatic stress disorder (PTSD) delivered by telehealth over the course of six-daily 60-minute sessions within a 10-day window. All study visits occur remotely, by telehealth. You will be asked to complete a pre-treatment assessment involving a clinical interview, video-based measures of emotional and physical reactions, such as heart rate and breathing rate, and self-report questionnaires to measure the severity and impact of trauma-related symptoms. These assessments are completed again 1-week, and 1-month after completing treatment. The researchers propose that massed exposure-based therapy delivered via telehealth will advance telemental health treatment options and personalized care for Veterans with PTSD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: VVC-delivered Massed Imaginal Exposure
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Telehealth-delivered Massed Imaginal Exposure for PTSD: Toward Increasing Access to Alternative, Evidence-based Treatment Schedules for Virtual Care
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Telehealth Massed Imaginal Exposure Therapy

Behavioral: VVC-delivered Massed Imaginal Exposure
Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.

Outcome Measures

Primary Outcome Measures

  1. Adverse events [from admission to 1 month follow up]

    Potential adverse events will be assessed with a structured as well as open-ended interview daily during treatment and at follow up.

  2. Satisfaction with treatment - provider [1 week post-treatment]

    PETQ: Prolonged exposure therapist questionnaire; scores range 0-30 with higher scores suggesting patient is more engaged in treatment.

  3. Satisfaction with telehealth - provider [1 week post-treatment]

    TTSQ-Provider: Technology Treatment Satisfaction Questionnaire; scores range 0-30 with higher scores suggesting patient is more engaged in treatment

  4. Satisfaction with treatment - patient [1 week post-treatment]

    STTSR: Satisfaction with Therapy and Therapist Scale-Revised; scores range 0-60 with higher scores indicating higher satisfaction

  5. Satisfaction with telehealth - patient [1 week post-treatment]

    Technology Treatment Satisfaction Questionnaire; scores range 0-60 with higher scores indicating higher satisfaction.

  6. Number of sessions attended per patient [from pre-treatment to 1-month follow-up]

    Number of telehealth therapy appointments attended per patient.

  7. Rate of treatment completion and pre-mature dropout. [from pre-treatment to 1-month follow-up]

    Total percent of patients retained from initial patients.

  8. CAPS: Clinician-Administered PTSD Scale for DSM-5 [from pre-treatment to 1-month follow-up]

    Structured interview for DSM-5 PTSD severity and impairment; Scores range from 0 to 80 with higher scores indicating greater PTSD severity and impairment.

  9. MINI Neuropsychiatric Interview Schedule [from pre-treatment to 1-month follow up]

    Assessment of DSM-5 diagnostic criteria for PTSD and comorbid conditions

  10. PTSD symptom checklist [from pre-treatment to 1-month follow-up]

    PCL-5: PTSD Symptom Checklist for DSM-5. Scores range from 0 to 80, with higher scores indicating greater PTSD severity and impairment.

Secondary Outcome Measures

  1. Remote photoplethysmography [Pre-treatment, 1-week post-treatment, and 1-month follow-up.]

    Video-based derivation of psychophysiology including heart rate and respiratory rate

  2. Facial emotional expressivity [Pre-treatment, 1-week post-treatment, and 1-month follow-up.]

    Video-based derivation of facial emotional expressivity.

  3. Vocal and linguistic emotional expressivity [Pre-treatment, 1-week post-treatment, and 1-month follow-up.]

    Audio-based derivation of vocal and linguistic emotional expressivity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18-65.

  • Ability to speak, read, and write English.

  • Diagnosis of PTSD based on CAPS-5 (> 3 mo. post-trauma).

  • Seeking treatment for PTSD at the Charleston VA.

  • Willingness and ability to engage in assessment and treatment visits through VVC, or another VA-approved telehealth videoconferencing platform.

Exclusion Criteria:
  • Currently receiving psychotherapy for another anxiety- or stress-related condition.

  • Current substance use disorder diagnosis with repeated abuse or dependence within 3 months of study entry and unwillingness to abstain for 24 hours prior to study visits.

  • Unstable dose of psychotropic medications within 6 weeks prior to baseline assessment (based on the DMSC; see measures).

  • Medical condition that would contraindicate participation in treatment or assessment activities (e.g., severe cardiovascular problems; based on MINI, DMSC, and chart review; see measures).

  • Current, or history of bipolar I disorder (based on MINI; see measures).

  • Current, or history of psychotic symptoms (based on MINI; see measures).

  • Serious suicidal risk or a suicide attempt in the past year, as determined by self-report (PHQ-9) and clinical interview (C-SSRS; see measures).

  • Active neurological conditions, e.g., seizures, stroke, loss of consciousness or concussion (based on MINI, DMSC, and chart review; see measures)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Medical University of South Carolina
  • Ralph H. Johnson VA Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lisa McTeague, PhD, Associate Professor, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT05450224
Other Study ID Numbers:
  • Pro00106523
First Posted:
Jul 8, 2022
Last Update Posted:
Jul 8, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lisa McTeague, PhD, Associate Professor, Medical University of South Carolina
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 8, 2022